

Treatment eligibility



Treatment
eligibility
criteria

Treatment
candidate

Contraindicated
patient



MRI-based contraindications

- A history of macrohemorrhages
- More than 4 microhemorrhages
- Evidence of superficial siderosis
- Evidence of brain vasogenic edema
- Significant white matter hyperintensities
- Multiple lacunar strokes
- Cerebral strokes involving a major vascular territory
- Central nervous system infection
- Evidence of cerebral contusion, encephalomalacia, brain aneurysms or other vascular malformations
- Brain tumors other than meningioma
- Arachnoid cysts
- Evidence of underlying cerebral amyloid angiopathy-related inflammation
- Evidence of Amyloid-Beta-related angiitis

Treatment eligibility

baba vision

Home

Patients

Reports

Timeline

Baseline2026-01-01

Assessments

MRI

T1
January 1, 2026

T2 FLAIR
January 1, 2026

T2*
January 1, 2026

SWI
January 1, 2026

Genetic Markers

APOE
January 2, 2026c3

TREM2
January 2, 2026R47H

Biological Tests

pTau217
January 2, 202690th

AB42/40
January 2, 202612th

NfL
January 2, 202686th


Settings

Support

SagittalCoronalAxial

3D

Sagittal112
Coronal126
Axial135



Treatment eligibility

Leqembi

Eligible

Kisunla

Not eligible

Disease status

Differential Diagnosis

93%
Alzheimer's disease

Disease stage

Stage 1/4
Mild cognitive impairment

Predicted progression rate

85th
Risk percentile

MRI contraindications

0
Macrohemorrhages


Absent
Vasogenic edema


2
Microhemorrhages

1
Lacunar strokes

Absent
Superficial siderosis


Moderate
White matter hyperintensity load





Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., Leisgang-Osse, A. M., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 11(2), e70098.

The future of Alzheimer's treatment



Thank you for your attention!
esten@baba-vision.com

baba vision

